Vertex Pharmaceuticals has reported promising clinical progress with its off-the-shelf stem cell therapy, zimislecel (formerly VX-880), for type 1 diabetes. In a cohort of twelve patients, ten were able to discontinue insulin injections a year after infusion, demonstrating robust endogenous insulin production and improved glycemic control. The Phase 1/2 study presented at the American Diabetes Association meeting and published in the New England Journal of Medicine showcased the therapy’s safety profile, absence of severe hypoglycemia events, and sustained efficacy. Zimislecel is derived from pluripotent stem cells engineered to differentiate into functional islet cells, offering a potential transformative alternative to exogenous insulin therapy. This advancement represents a significant milestone in regenerative medicine approaches to diabetes management.